Migration of CD4 T Cells and Dendritic Cells toward Sphingosine 1-Phosphate (S1P) Is Mediated by Different Receptor Subtypes: S1P Regulates the Functions of Murine Mature Dendritic Cells via S1P Receptor Type 3

Yasuhiro Maeda, Hirofumi Matsuyuki, Kyoko Shimano, Hirotoshi Kataoka, Kunio Sugahara and Kenji Chiba

J Immunol 2007; 178:3437-3446; doi: 10.4049/jimmunol.178.6.3437
http://www.jimmunol.org/content/178/6/3437

References
This article cites 52 articles, 20 of which you can access for free at:
http://www.jimmunol.org/content/178/6/3437.full#ref-list-1

Subscription
Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Migration of CD4 T Cells and Dendritic Cells toward Sphingosine 1-Phosphate (S1P) Is Mediated by Different Receptor Subtypes: S1P Regulates the Functions of Murine Mature Dendritic Cells via S1P Receptor Type 3

Yasunori Maeda, Hirofumi Matsuuki, Kyoko Shimano, Hiroshi Kataoka, Kunio Sugahara, and Kenji Chiba

Dendritic cells (DCs) and lymphocytes are known to show a migratory response to the phospholipid mediator, sphingosine 1-phosphate (S1P). However, it is unclear whether the same S1P receptor subtype mediates the migration of lymphocytes and DCs toward S1P. In this study, we investigated the involvement of S1P receptor subtypes in S1P-induced migration of CD4 T cells and bone marrow-derived DCs in mice. A potent S1P receptor agonist, the (S)-enantiomer of FTY720-phosphate ([S]-FTY720-P), at 0.1 nM or higher and a selective S1P receptor type 1 (S1P1) agonist, SEW2871, at 0.1 μM or higher induced a dose-dependent down-regulation of S1P1. The pretreatment with these compounds resulted in a significant inhibition of mouse CD4 T cell migration toward S1P. Thus, it is revealed that CD4 T cell migration toward S1P is highly dependent on S1P1. Mature DCs, when compared with CD4 T cells or immature DCs, expressed a relatively higher level of S1P3 mRNA. S1P at 10–100 nM induced a marked migration and significantly enhanced the endocytosis of FITC-dextran in mature but not immature DCs. Pretreatment with (S)-FTY720-P at 0.1 μM or higher resulted in a significant inhibition of S1P-induced migration and endocytosis in mature DCs, whereas SEW2871 up to 100 μM did not show any clear effect. Moreover, we found that S1P-induced migration and endocytosis were at an extremely low level in mature DCs prepared from S1P3-knockout mice. These results indicate that S1P regulates migration and endocytosis of murine mature DCs via S1P3 but not S1P1.

patches and thereby decreases the number of lymphocytes in peripheral blood, thoracic duct lymph, and the spleen (14). In addition, Yagi et al. (21) reported that FTY720 inhibits mature thymocyte emigration from the thymus to the periphery in mice. It has been demonstrated that FTY720 is phosphorylated to a (5)-enantiomer of FTY720-phosphate ([5]-FTY720-P) by SPHK1a and SPHK2 (22, 23). (5)-FTY720-P acts as an agonist at S1P receptors except for S1P3, internalizes S1P1 on lymphocytes, and thereby inhibits the migration of lymphocytes toward S1P (24). Consequently, treatment with FTY720 down-regulates S1P1 and creates a temporary pharmacological S1P1-null state in lymphocytes. This provides an explanation for the mechanism of FTY720-induced lymphocyte sequestration. It is likely that FTY720 reduces circulating lymphocytes by inhibiting S1P1/S1P3-dependent lymphocyte egress from secondary lymphoid tissues and the thymus.

DCs, as well as lymphocytes, are key constituents of the immune system. DCs play pivotal roles in the induction of Ag-specific immune responses as powerful APCs (25–27). In contrast to immune system. DCs play pivotal roles in the induction of Ag-specific immune responses as powerful APCs (25–27). In contrast to

Reagents and Abs

An active metabolite of FTY720, (5)-FTY720-P, was synthesized with high enantioselectivity (>99.5% enantiomer excess) in Mitsubishi Pharma according to the method as previously described (24) and dissolved in ethanol. S1P, selective agonist, SEW2871 (31), was also synthesized in Mitsubishi Pharma. S1P, FITC-dextran (FITC-Dx), and LPS were purchased from Sigma-Aldrich. Recombinant mouse (rm)-GM-CSF, rm-CCL21, and anti-human S1P1 mAb were purchased from R&D Systems. Anti-HA polyclonal Ab (Y-11) and Alexa 488-conjugated anti-rabbit IgG were obtained from Santa Cruz Biotechnology. FITC-conjugated mouse anti-human CD4 mAb (RPA-T4) and PE-Cy5-conjugated mouse anti-human CD3 mAb (UCHT1) were purchased from eBioscience. FITC-, PE-, CyChrome-, or biotin-conjugated mAbs recognizing the following mouse surface markers were obtained from BD Biosciences: CD4 (GK1.5), CD3 (RA3-6B2), CD8 (53-6.7), CD11c (HL.3), CD86 (GL1), I-Ag4 (KH74), CD40 (3/23), and CD80 (16-10A1). PE-conjugated goat anti-mouse Ig-specific polyclonal Ab and streptavidin-CyChrome conjugate were also purchased from BD Biosciences.

Human S1P1 expression in CHO cells

Chinese hamster ovary (CHO) cells purchased from Dainippon Pharmaeutical were transfected with DNAs encoding human S1P1, using LipofectAMINE (Invitrogen Life Technologies). Then the cells stably expressing human S1P1 (hS1P1-CHO cells) were selected in Ham’s F-12 medium (Sigma-Aldrich) supplemented with 10% FCS (Invitrogen Life Technologies) and 600 μg/ml geneticin (Sigma-Aldrich) at 37°C. hS1P1-CHO cells were grown on culture dishes, followed by serum starvation by RPMI 1640 medium supplemented with 10 mM HEPES, 100 U/ml penicillin, 60 μg/ml kanamycin sulfonate, 50 μM 2-ME, and 0.5% fatty acid-free BSA (Sigma-Aldrich) for 18 h at 37°C, and were incubated with S1P, (5)-FTY720-P, or SEW2871 at various concentrations for 1 h at 37°C. After the incubation, the cells were collected and stained with anti-human S1P1 mAb (1D3), anti-isotype-matched control IgG, followed by detection with PE-conjugated goat anti-mouse Ig-specific polyclonal Ab. The expression of human S1P1 on the cell surface was analyzed by flow cytometry with FACScan (BD Biosciences), and the results were expressed as the mean fluorescence intensity of triplicate determinations.

SIP1 expression in CHO cells

CHO cells stably expressing C-terminal hemagglutinin (HA)-tagged mouse S1P1 (mS1P1-CHO cells) were obtained by transfection as described above. mS1P1-CHO cells were grown on Lab-Tek chamber slide (Nunc), followed by serum starvation for 18 h, and then incubated with S1P, (5)-FTY720-P, or SEW2871 at various concentrations. After incubation, the cells were washed and fixed with 3.7% formaldehyde in PBS at room temperature for 20 min. After permeabilization and blocking, the cells were stained with anti-HA polyclonal Ab, followed by detection with Alexa 488-conjugated anti-rabbit IgG. The slides were rinsed in water and mounted on glass slides using Mowiol 4-88 (Calbiochem). The images were digitally captured under a confocal laser microscope (Carl Zeiss).

Preparation of mouse CD4 T cells from spleen

Spleens were removed from mice and single-cell suspensions were prepared by mincing and passing through stainless mesh. After removing RBCs by lysis with Tris-NH4Cl solution, the spleen cells were suspended in RPMI 1640 medium with 0.5% fatty acid-free BSA. For real-time PCR analysis, the spleen cells were purified to >95% of CD4 T cells by passing through mouse CD4 subset enrichment columns (R&D Systems).

Preparation of DCs from bone marrow

DCs were prepared from mouse bone marrow cells according to the method as described Son et al. (32). Briefly, the bone marrow cells were flushed out from femurs and tibias using RPMI 1640 medium and were passed through cotton to remove bone marrow particles. After removing RBCs by Tris-NH4Cl solution, the bone marrow cells were suspended in RPMI 1640 medium supplemented with 10 mM HEPES, 100 U/ml penicillin, 60 μg/ml kanamycin sulfonate, 50 μM 2-ME, 10% FCS, and 10 μg/ml rm-GM-CSF. The bone marrow cells at 2 × 10^6 cells/ml were cultured in 6-well plates at 37°C in 5% CO2, and 10 μg/ml rm-GM-CSF was added on day 4 of the culture. After culturing for 6 days, both nonadherent and loosely adherent cells were collected and purified to >95% of CD11c^+.
immature DCs by incubation with anti-CD11c MACS beads (Miltenyi Bio tec) for 15 min at 4°C, followed by two cycles of MACS-positive selection. In some experiments, immature DCs at 5 × 10^5 cells/ml in 10-cm culture dishes were cultured for an additional 24 h with LPS (1 µg/ml). More than 90% of I-A^β high/CD86 high mature DCs were obtained by LPS-stimulation of immature DCs as determined by flow cytometry with FACSscan. For real-time PCR analysis, each of immature and mature DCs was further purified to >98% of I-A^β high/CD86 high immature and I-A^β high/CD86 high mature DCs by a MoFlo cell sorter (DakoCytometry).

Chemotaxis assays

Migration assays were conducted according to the method described previously (34). After serum starvation using RPMI 1640 medium with 0.5% fatty acid-free BSA for 3 h at 37°C, spleen cells or bone marrow-derived DCs (5 × 10^5 cells) were added to the upper wells of 5-µm pore, polycarbonate 24-well tissue culture inserts (Costar) in 100 µl, with 600 µl of S1P, (S)-FTY720-P, or rm-CCL21 dilution (or medium) in the bottom wells. Three chemotactic wells were set up for each chemotactic agent. All migration assays were conducted in RPMI 1640 medium with 0.5% fatty acid-free BSA for 3 h at 37°C in 5% CO2. In some experiments, the cells were pretreated with (S)-FTY720-P, or rm-CCL21 dilution (or medium) in the bottom wells. Three chemotactic wells were set up for each chemotactic agent. All migration assays were conducted in RPMI 1640 medium with 0.5% fatty acid-free BSA for 3 h at 37°C in 5% CO2. In some experiments, the cells were pretreated with (S)-FTY720-P or SEW2871 for 5 min. The migrated cells recovered from each well were counted using comparison to a known number of beads as an internal standard of Flow-Count fluorosphere. The number of beads was used to record the migration of input cells toward S1P on the microchannel. As shown in Fig. 2, S1P (10–1000 nM), (S)-FTY720-P at 0.1–10 nM, and SEW2871 (100–10,000 nM) induced a dose-dependent down-regulation of human S1P1, ohS1P1-CHO cells. In human CD4 T cells, these compounds also induced a dose-dependent down-regulation of S1P1 (Fig. 1B). Particularly, S1P at 1,000 nM and (S)-FTY720-P at 1 nM or higher induced a marked down-regulation of S1P1 in human CD4 T cells. Fig. 1C shows the dose-response relationships of (S)-FTY720-P, S1P, and SEW2871 on S1P down-regulation in hS1P1-CHO cells. (S)-FTY720-P at 0.1 nM or higher induced a significant and dose-dependent down-regulation of S1P1 with IC50 of 0.44 nM, and the cell surface expression of S1P1 on hS1P1-CHO cells was reduced almost completely at 10 nM or higher. S1P also induced a dose-dependent down-regulation of S1P1 at 30–300 nM with IC50 of 98 nM and a maximal down-regulation at 1,000 nM. Furthermore, SEW2871 induced S1P1 down-regulation at 300–1,000 nM with IC50 of 480 nM, and a marked down-regulation was observed only at high concentrations (>3,000 nM). Similar results were obtained when human CD4 T cells were treated with (S)-FTY720-P, S1P, and SEW2871 (data not shown).

S1P receptor agonists induce S1P1 down-regulation in mS1P1-CHO cells and inhibit mouse CD4 T cell migration toward S1P

To examine the effect of S1P, (S)-FTY720-P, and a selective S1P1 agonist, SEW2871, on S1P1 down-regulation using hS1P1-CHO cells and mAb specific against human S1P1 by flow cytometry. As shown in Fig. 3A, S1P (10–1000 nM), (S)-FTY720-P at 0.1–10 nM, and SEW2871 (100–10,000 nM) induced a dose-dependent down-regulation of human S1P1, ohS1P1-CHO cells. In human CD4 T cells, these compounds also induced a dose-dependent down-regulation of S1P1 (Fig. 1B). Particularly, S1P at 1,000 nM and (S)-FTY720-P at 1 nM or higher induced a marked down-regulation of S1P1 in human CD4 T cells. Fig. 1C shows the dose-response relationships of (S)-FTY720-P, S1P, and SEW2871 on S1P down-regulation in hS1P1-CHO cells. (S)-FTY720-P at 0.1 nM or higher induced a significant and dose-dependent down-regulation of S1P1 with IC50 of 0.44 nM, and the cell surface expression of S1P1 on hS1P1-CHO cells was reduced almost completely at 10 nM or higher. S1P also induced a dose-dependent down-regulation of S1P1 at 30–300 nM with IC50 of 98 nM and a maximal down-regulation at 1,000 nM. Furthermore, SEW2871 induced S1P1 down-regulation at 300–1,000 nM with IC50 of 480 nM, and a marked down-regulation was observed only at high concentrations (>3,000 nM). Similar results were obtained when human CD4 T cells were treated with (S)-FTY720-P, S1P, and SEW2871 (data not shown).

S1P1 receptor agonists induce S1P1 down-regulation in mS1P1-CHO cells and inhibit mouse CD4 T cell migration toward S1P

To examine the effect of S1P, (S)-FTY720-P, and SEW2871 on mouse S1P1 down-regulation, we used HA-tagged mS1P1-CHO cells and mAb specific against HA because there is no available anti-mouse S1P1 mAb for flow cytometric analysis. Fig. 2 shows representative data. Both S1P and (S)-FTY720-P induced rapid S1P1 down-regulation in mS1P1-CHO cells. S1P1 down-regulated by S1P recycled back to the plasma membrane at 3 h, whereas a long-term down-regulation of S1P1 was induced by (S)-FTY720-P in mS1P1-CHO cells.

Next, we examined the inhibitory effect of (S)-FTY720-P and SEW2871 on the migration of CD4 T cells toward S1P by Transwell assay. Consistent with our data previously reported (24), CD4 T cells showed a significant migratory response toward S1P in a dose-dependent manner, peaking at 10 nM (Fig. 3A, □). In addition, we found that (S)-FTY720-P at 0.1–1 nM could also induce CD4 T cell migration, although its activity was about half that of S1P (Fig. 3A, □). Furthermore, SEW2871 at 1000 nM also induced CD4 T cell migration (data not shown). The migration of CD4 T cells toward 10 nM S1P was inhibited significantly and in a dose-dependent manner by pretreatment with (S)-FTY720-P at 0.1 nM or higher with IC50 of 0.22 nM (Fig. 3B). Particularly,
pretreatment with (S)-FTY720-P at 1 nM or higher resulted in almost complete inhibition of S1P-induced CD4 T cell migration. SEW2871, like (S)-FTY720-P, almost completely inhibited S1P-induced CD4 T cell migration at concentrations of 300 nM or higher with IC\textsubscript{50} of 220 nM (Fig. 3C). From these data, it is strongly suggested that inhibition of S1P-induced CD4 T cell migration by (S)-FTY720-P or SEW2871 is caused by the down-regulation of S1P\textsubscript{1}. Thus, we confirmed that the migration of CD4 T cells toward S1P is highly dependent on S1P\textsubscript{1}.

FIGURE 1. The effect of S1P receptor agonists on the expression of S1P\textsubscript{1} in hS1P\textsubscript{1}-CHO cells and human CD4 T cells. After serum starvation for 18 h, hS1P\textsubscript{1}-CHO cells or human CD4 T cells were incubated with (S)-FTY720-P (○), S1P (●), and SEW2871 (△) for 1 h at 37°C. Cell surface expression of S1P\textsubscript{1} was determined by flow cytometry. The typical results of S1P\textsubscript{1} down-regulation induced by S1P receptor agonists in hS1P\textsubscript{1}-CHO cells (A) and human CD4 T cells (B). Human CD4 T cells were determined by staining with anti-CD3 and anti-CD4 mAbs. C, The results of hS1P\textsubscript{1}-CHO cells were expressed as the mean fluorescence intensity in triplicate determinations.

FIGURE 2. The effect of S1P and (S)-FTY720-P on the expression of S1P\textsubscript{1} in mS1P\textsubscript{1}-CHO cells. After serum starvation for 18 h, mS1P\textsubscript{1}-CHO cells were incubated with 100 nM S1P (upper panels) or (S)-FTY720-P (lower panels) at 37°C. At indicated times, the cells were fixed, permeabilized, and then stained with rabbit anti-HA polyclonal Ab and Alexa 488-conjugated anti-rabbit IgG.

FIGURE 3. The effect of S1P receptor agonists on mouse CD4 T cell migration. A, After serum starvation for 3 h, mouse spleen cells were performed to migration assays toward 0.01–1000 nM S1P (▲) or (S)-FTY720-P (○). The percent migration of CD4 T cells was determined by flow cytometry, and the results were expressed as the mean ± SEM of triplicate wells. **, p < 0.01, when compared with medium control (Dunnett’s test). B and C, After serum starvation, the spleen cells were pretreated with 0.1–3 nM (S)-FTY720-P (B) or 100–3000 nM SEW2871 (C) for 5 min, and then migration assays toward 10 nM S1P were performed. The migration of CD4 T cells toward medium alone or S1P at 10 nM was designated as 0 or 100%, respectively. Data are expressed as the mean ± SEM of triplicate wells. ***, p < 0.01, when compared with S1P-induced CD4 T cell migration (Dunnett’s test).
SIP induces migration of mature, but not immature, DCs

We examined the effect of SIP, (S)-FTY720-P, and SEW2871 on mouse bone marrow-derived DCs. On day 6 of culture, CD11c+ cells were sorted by MACS column and used as immature DCs. Following treatment with LPS for 24 h, DCs exhibited a mature phenotype with increased expression of CD86 and MHC class II (I-A^b) molecules and were used as mature DCs. These immature and mature DCs were discriminated by their expression profile (immature DCs, CD86low I-Ab intermediate; mature DCs, CD86high I-Ab high) and were used in a chemotaxis assay to analyze their response to SIP, (S)-FTY720-P, and SEW2871.

SIP at 10–1000 nM induced a strong migratory response in mature DCs, with migration of ~70–90% of input cells (Fig. 4A, □). To confirm a mature differentiation status of the tested DCs, migration was examined in response to the CCR7 ligand CCL21, known as a strong chemotactic inducer for mature DCs (27, 35–37). The treatment with rm-CCL21 at 500 ng/ml led to a potent migration comparable to that of SIP. In contrast, we did not observe any clear migration of mouse immature DCs toward SIP up to 1000 nM or rm-CCL21 (Fig. 4A, ▢). The addition of SIP to both sites of the filter revealed that both chemotaxis and chemokinesis contribute to the SIP-mediated cell motility (data not shown). By conducting the real-time chemotaxis assay using a microchemotaxis chamber, most of the mature DCs were found to start migrating toward the SIP gradient after 10 min (Fig. 4B).

These migrating cells spread lamellipodium widely toward the high concentration of SIP. In contrast, no directional migration was observed when immature DCs were incubated with SIP in the chamber (data not shown).

As shown in Fig. 4C, SIP induced a marked migration, whereas (S)-FTY720-P at 100 nM produced only a slight, but significant, migratory response in mature DCs (Fig. 4C, □). However, SEW2871 did not induce the migration of mature DCs (data not shown). When mature DCs were pretreated with (S)-FTY720-P for 5 min, the migration toward 10 nM SIP was inhibited, partially at 100 nM and completely at 1000 nM or higher concentrations, respectively, with IC_{50} of 97 nM (Fig. 4D). However, the amount of (S)-FTY720-P necessary to inhibit the migration of mature DCs was ~1000-fold higher than that of CD4 T cells (Figs. 3B and 4D). In contrast, SEW2871, which inhibits SIP-induced CD4 T cell migration, did not show any clear effect on SIP-induced mature

![FIGURE 4.](#) The effect of SIP receptor agonists on the migration of immature and mature DCs. A. After serum starvation for 3 h, immature (imDCs; □) and mature DCs (mDCs; ■) derived from bone marrow cells were performed to migration assays toward 1–1000 nM SIP or 500 ng/ml rm-CCL21. The percent migration of imDCs and mDCs was determined by flow cytometry, and the results were expressed as the mean ± SEM of triplicate wells. **, p < 0.01, when compared with medium control (t test); ***, p < 0.01, when compared with medium control (Dunnett’s test). B. After serum starvation, 1 μl of 1 × 10^6 mDCs was put into one hole of the microchemotaxis chamber, and 1 μl of 10 μM SIP was put into another hole. A charge-coupled device camera was used to record the migration of mDCs under the gradiation of SIP. C. Migration assays of mDCs toward 1–1000 nM SIP (□) or (S)-FTY720-P (□) were performed. Data are expressed as the mean ± SEM of triplicate wells. **, p < 0.05; ***, p < 0.01, when compared with medium control (Dunnett’s test). D and E. After the pretreatment with 0.01–10 μM (S)-FTY720-P (D) or 0.1–100 μM SEW2871 (E) for 5 min, mDCs were performed to migration assays toward 100 nM SIP. The migration of mDCs toward medium alone or SIP at 100 nM was designated as 0 or 100%, respectively. Data are presented as the mean ± SEM of triplicate wells. **, p < 0.01, when compared with SIP-induced mDC migration (Dunnett’s test).

![FIGURE 5.](#) The effect of SIP on the endocytosis of FITC-Dx by immature and mature DCs. A and B. After serum starvation, immature (imDCs; □) and mature DCs (mDCs; ■) were incubated with 1 mg/ml FITC-Dx in the presence or absence of 100 nM SIP for 2–60 min. The percentage of FITC+ DC population was determined by flow cytometry, and the results were expressed as the mean ± SEM of triplicate wells. **, p < 0.01, when compared with SIP-untreated control (t test). ∆, imDCs; ▲, imDCs incubated with SIP; ○, mDCs; ●, mDCs incubated with SIP.
SEW2871 (C) for 5 min, mDCs were performed to migration assays toward 1–1000 nM S1P (S) or (R)-DCs (mDCs) were incubated with 1 mg/ml FITC-Dx in the presence of DC migration in the range of 0.1–100/H9262 expressed as the mean/H11006. The effect of (S)-FTY720-P and SEW2871 on S1P-induced endocytosis of FITC-Dx by mature DCs. After serum starvation, mature DCs (mDCs) were incubated with 1 mg/ml FITC-Dx in the presence of 1–1000 nM S1P (B) or (S)-FTY720-P (B) for 2 min. The results were expressed as the mean ± SEM of triplicate wells. *, p < 0.05; **, p < 0.01, when compared with medium control (Dunnett’s test). B and C. After the pretreatment with 0.01–10 μM (S)-FTY720-P (B) or 0.1–100 μM SEW2871 (C) for 5 min, mDCs were performed to migration assays toward 100 nM S1P. The migration of mDCs toward medium alone or S1P at 100 nM was designated as 0 or 100%, respectively. Data are presented as the mean ± SEM of triplicate wells. **, p < 0.01, when compared with S1P-induced mDC migration (Dunnett’s test).

DC migration in the range of 0.1–100 μM (Fig. 4E). These results suggest that different S1P receptor subtypes mediate the migration of CD4 T cells and mature DCs toward S1P.

**SIP enhances endocytosis in mature DCs**

We examined the effect of S1P on endocytosis of FITC-Dx in immature and mature DCs. Approximately 80% of immature DCs became FITC-Dx positive after 60 min of incubation and S1P at 100 nM did not influence FITC-Dx uptake by immature DCs (Fig. 5A). On the contrary, the proportion of FITC-Dx-positive mature DCs at 60 min was <26.0% of the total cells and was significantly increased to 45.0% after treatment with S1P for 2 min (Fig. 5B). As shown in Fig. 6A, treatment with S1P at 10–1000 nM significantly increased the endocytosis of FITC-Dx by mature DCs in a dose-dependent manner and only a high concentration (1000 nM) of (S)-FTY720-P slightly, but significantly, enhanced the endocytosis of mature DCs. Moreover, pretreatment with (S)-FTY720-P resulted in an inhibitory effect on S1P-induced endocytosis of mature DCs at 100 nM or higher concentrations (Fig. 6B).

In contrast, SEW2871 did not show any clear effect on the endocytosis of mature DCs, suggesting that S1P-induced endocytosis is independent on S1P1 (Fig. 6C).

**The mRNA expression patterns of S1P receptors in CD4 T cells and immature and mature DCs in mice**

Because there are significant differences in the responsiveness of mouse mature DCs and CD4 T cells for S1P, (S)-FTY720-P, and SEW2871 (Figs. 3 and 4), we further characterized the involvement of specific receptors. To analyze the mRNA expression patterns of S1P receptors on CD4 T cells and immature and mature DCs, we performed real-time PCR analysis for S1P receptor mRNAs. The mRNA expression of S1P1 and S1P4 was the most prominent on CD4 T cells (Table I). Furthermore, we found subtype-specific differential expression of S1P1-5 mRNA between immature and mature DCs (Table I). Especially, the expression level of S1P1 mRNA was massively increased in mature DCs (>20-fold), whereas S1P1 and S1P4 mRNA levels showed approximately a 2-fold increase and a slight decrease (0.7-fold), respectively. In contrast, both differentiation stages showed similar expression patterns of S1P2 and S1P5. It showed clearly a lower expression level of S1P1 mRNA in mature DCs than in CD4 T cells, whereas the expression level of S1P1 mRNA in mature DCs was higher than that in CD4 T cells (Table I).

**SIP3 is essential for S1P-induced migration and endocytosis of mature DCs but not CD4 T cells**

Because S1P1 was expressed more abundantly in mature DCs than immature DCs, we used S1P3-knockout mice to test whether this receptor was required in mature DC migration toward S1P. Mature DCs prepared from S1P3-knockout mice had similar expression levels of S1P1, S1P2, S1P3, and S1P4 mRNA transcripts compared with those from littermate control mice; however these cells showed an extremely low level of migration toward S1P (Fig. 7, A and B). Furthermore, S1P at concentrations up to 1000 nM could not enhance the endocytosis of FITC-Dx in mature DCs prepared from S1P3-knockout mice (Fig. 7C). To confirm a mature differentiation status of the LPS-treated DCs from S1P3-knockout mice, we performed phenotypic analysis and chemotaxis assays. The expression levels of CD40, CD80, CD86, and MHC class II (I-Ab), and the chemotactic responsiveness to rm-CCL21 in mature DCs was indistinguishable between S1P3-knockout mice and littermate control mice (Fig. 7, D and E). These results demonstrated that S1P induces not only migration but also endocytosis in mature DCs via S1P3.

There was no significant difference in the mRNA levels of S1P receptors, except for S1P3, in CD4 T cells between S1P3-knockout mouse

<table>
<thead>
<tr>
<th>Table I.</th>
<th>The mRNA expression patterns of S1P receptors in CD4 T cells and immature and mature DCs in mice*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S1P1</td>
</tr>
<tr>
<td>CD4 T cells</td>
<td>5.73 ± 0.14</td>
</tr>
<tr>
<td>Immature DCs</td>
<td>0.14 ± 0.01</td>
</tr>
<tr>
<td>Mature DCs</td>
<td>0.25 ± 0.02</td>
</tr>
</tbody>
</table>

*Real-time quantitative PCR analysis of the mouse S1P receptors in CD4 T cells and immature and mature DCs was performed as described in Materials and Methods. The amount of product for each PCR was calculated from the incorporation of SYBR green and normalized to GAPDH. (Mean ± SEM of individual three experiments.)
and wild-type mice (Fig. 8A). As shown in Fig. 8B, in vivo administration of (S)-FTY720-P at 1 mg/kg i.v. to S1P3-knockout and wild-type mice resulted in indistinguishable reduction of CD4 T cells in peripheral blood. Similar data were obtained in the number of total lymphocytes, CD3 T cells, and CD8 T cells in peripheral blood from both types of mice after treatment with (S)-FTY720-P (data not shown). Thus, we confirmed that S1P/S1P3 interaction is not essential to reduce circulating lymphocytes by (S)-FTY720-P administration. In addition, the migratory response toward S1P and the inhibitory effect of (S)-FTY720-P on S1P-induced migration in CD4 T cells showed almost the same patterns between S1P3-knockout and wild-type mice (Fig. 8, C and D). Based on these results, we concluded that S1P3 and S1P1 mediated S1P-induced migration of murine mature DCs and CD4 T cells, respectively.

**Discussion**

In the immune system, S1P is involved in immune cell migration, proliferation, differentiation, and cytokine production (5–7). Five types of specific receptors for S1P, termed S1P1–S5, are suggested to play several roles in the immune systems; however, their precise involvement in the function of immune cells remains unclear. Recently, results from gene-targeted mice have revealed that inter- and intracellular S1P receptors are essential for immune cell migration (8). S1P1 down-regulation and inhibition of T cell migration by (S)-FTY720-P administration. In addition, the migratory response toward S1P and the inhibitory effect of (S)-FTY720-P on S1P-induced migration in CD4 T cells showed almost the same patterns between S1P3-knockout and wild-type mice (Fig. 8, C and D). Based on these results, we concluded that S1P3 and S1P1 mediated S1P-induced migration of murine mature DCs and CD4 T cells, respectively.

**FIGURE 8.** S1P3 is not essential for S1P-induced migration of mouse mature DCs. A, Quantitative PCR analysis of S1P receptors in mature DCs (mDCs) from S1P3 wild-type (WT; ■) or S1P3-knockout (S1P3-KO; □) mice expressed as relative amount of mRNA normalized to GAPDH. B, After serum starvation for 3 h, mDCs from WT (■) or S1P3-KO (□) mice were performed to migration assays toward 1–1000 nM S1P (B) or 500 ng/ml rm-CCL21 (E). The percent migration of mDCs was determined by flow cytometry, and the results were expressed as the mean ± SEM of triplicate wells. ***, p < 0.01, when compared with medium control (Dunnett’s test).**, *, p < 0.05, when compared with wild-type mice (Dunnett’s test). C, Migratory response of mature DCs from WT or S1P3-KO mice were performed to migration assays toward 1–1000 nM S1P. The migration of CD4 T cells toward medium alone or S1P was designated as 0 or 100%, respectively. The results were expressed as the mean ± SEM of triplicate wells. *, p < 0.05; ***, p < 0.01, when compared with S1P-induced migration (Dunnett’s test).

**FIGURE 7.** S1P3 is essential for S1P-induced migration and endocytosis of mouse mature DCs. A, Quantitative PCR analysis of S1P receptors in mature DCs (mDCs) from S1P3 wild-type (WT; ■) or S1P3-knockout (S1P3-KO; □) mice expressed as relative amount of mRNA normalized to GAPDH. B and E, After serum starvation for 3 h, mDCs from WT (■) or S1P3-KO (□) mice were incubated with 1 mg/ml FITC-Dx in the presence of 1–1000 nM S1P for 2 min. The percentage of FITC+ mDC population was determined by flow cytometry, and the results were expressed as the mean ± SEM of triplicate wells. ***, p < 0.01, when compared with medium control (Dunnett’s test).**, *, p < 0.05, when compared with wild-type mice (Dunnett’s test). C, Peripheral blood CD4 T cells by t test.
In this study, we clarified the dose-response relationship of (S)-FTY720-P between S1P, down-regulation and the inhibition of CD4 T cell migration using (S)-FTY720-P with high enantiomeric selectivity (>99.5%). We, for the first time, demonstrated that (S)-FTY720-P at a concentration of 1 nM or higher induced a marked down-regulation of S1P1 in human CD4 T cells as well as hS1P1-CHO cells (Fig. 1). At the same concentration range, S1P-induced migration of mouse CD4 T cells was almost completely inhibited by pretreatment with (S)-FTY720-P (Fig. 3B). In addition, we found that CD4 T cells can migrate toward lower concentrations of (S)-FTY720-P (Fig. 3A). Because (S)-FTY720-P at 0.1–1 nM partially induced S1P1 down-regulation, it is presumed that residual S1P1 on the surface of lymphocytes can respond to (S)-FTY720-P. Similar results were obtained when S1P and the S1P1-selective agonist, SEW2871, were used (data not shown). Thus, it is likely that promotion or inhibition of CD4 T cell migration toward S1P depends on the magnitude of S1P1 down-regulation by S1P, (S)-FTY720-P, or SEW2871. SEW2871 has been reported to induce S1P1 internalization and recycling but not receptor degradation (31), and long-term, in vitro treatment with SEW2871 induces a marked decrease in peripheral blood lymphocytes in mice (39). Like FTY720, SEW2871 reduces the circulating lymphocytes by sequestering lymphocytes into secondary lymphoid tissues and the thymus (39). We showed here that SEW2871 inhibits S1P-induced migration of CD4 T cells at concentrations that induce internalization of S1P1 (Figs. 1 and 3C). These results indicated that S1P-induced CD4 T cell migration is mediated by S1P1.

It has been demonstrated that DCs, as well as lymphocytes, migrate to S1P; however, several studies have observed differences in the responsiveness of immature and mature DCs to S1P (28). Idzko et al. (28) described that, by using DCs derived from human monocyte, both immature and mature DCs show similar mRNA expression patterns to S1P1, S1P2, S1P3, and S1P4 and that S1P stimulates a pertussis toxin-sensitive (Gi-sensitive) Ca2+ increase, actin polymerization, and chemotaxis of immature, but not mature, DCs. In contrast, it has been reported that, by using mouse DCs prepared from bone marrow cells, TNF-α/PGE2-stimulated mature DCs express relatively higher mRNA levels of S1P1 and S1P3 and show a strong migratory response toward S1P, compared with immature DCs (29). The same pattern of S1P receptor expression was observed on DCs that reside in draining lymph nodes after FITC painting in vivo. Lan et al. (40) reported that immature DCs from blood, spleen, and bone marrow-derived DCs in mice express the mRNA of all five S1P receptors, and mRNA expression of S1P1, S1P2, and S1P3 is elevated in bone marrow-derived mature DCs after LPS stimulation. LPS-matured DCs exhibit a modest, but significant, migratory response to S1P, corresponding to the higher expression of S1P1, S1P3 mRNA on these DCs (40). Radeke et al. (41) provided evidence that S1P1 and S1P3, but not S1P4, are responsible for the S1P-induced migratory response in murine Langerhans cell line, XS52 cells.

Consistent with previous studies that used mouse bone marrow-derived DCs (29), our results in this study revealed that S1P, at 10–1000 nM, can induce the migration of LPS-matured but not immature DCs derived from mouse bone marrow cells (Fig. 4A). By using real-time PCR analysis, we have found that mature DCs, as compared with CD4 T cells or immature DCs, expressed relatively higher levels of S1P1 mRNA (Table I). There are three differences in migratory responses between CD4 T cells and mature DCs: 1) the dose-response relationship between S1P concentrations and S1P-induced migration; 2) the inhibitory concentration of (S)-FTY720-P for S1P-induced migration; and 3) the inhibitory effect of SEW2871 on S1P-induced migration.

The migratory response of CD4 T cells was induced by S1P at 10–100 nM but was decreased at 1000 nM (Fig. 3A). On the contrary, the migration of mature DCs was increased by S1P at 10–1000 nM in a dose-dependent manner (Fig. 4A). Pretreatment with (S)-FTY720-P resulted in a marked inhibition of S1P-induced CD4 T cell migration at 1 nM or higher; however, the inhibition of mature DC migration by (S)-FTY720-P was observed at 100 nM or higher (Figs. 3B and 4D). (S)-FTY720-P strongly induces S1P1 inactivation via receptor down-regulation, thereby inhibiting the migration of CD4 T cells toward S1P in a noncompetitive manner. Because it has been reported that S1P3, unlike S1P1, is not down-regulated by agonist stimulation (42), the higher concentration of (S)-FTY720-P may be required for the inhibition of S1P-induced migration of mature DCs. Furthermore, pretreatment of SEW2871 inhibited S1P-induced migration of CD4 T cells but not mature DCs. These observations strongly suggested that S1P-induced migration of CD4 T cells and mature DCs was regulated by a differential mechanism.

Because mRNA expression of S1P3 was relatively high in mature DCs and SEW2871 did not affect S1P-induced mature DC migration, it is highly probable that the migration of mature DCs toward S1P is mediated by S1P3 but not S1P1. To confirm this hypothesis, we performed chemotaxis assays using S1P3-knockout mice. As expected, mature DCs that lacked S1P3 could not migrate toward S1P, whereas CD4 T cells prepared from S1P3-knockout mice reacted to S1P as well as CD4 T cells from wild-type mice (Figs. 7B and 8, C and D). Consequently, we concluded that S1P-induced migration of mature DCs is mediated by S1P3, but not S1P1.

DCs developmentally regulate the activity of endocytosis: immature DCs exhibit vigorous acquisition of fluid-phase molecules, whereas mature DCs capture only low levels of exogenous Ags (43, 44). In this study, we found that a short exposure to S1P markedly enhanced endocytosis of FITC-Dx by mature but not immature DCs (Fig. 5). Endocytosis, as well as migration, of mature DCs induced by S1P was also at an extremely low level in S1P3-knockout mice, suggesting that S1P induced dextran endocytosis in mature DCs via S1P3. Yanagawa and Onoe (45) reported that the CCR7-ligand chemokines, CCL19 and CCL21, induce not only chemotaxis but also dextran endocytosis by mature DCs. Thus, it is likely that S1P and homing chemokines share certain characteristics of function, such as induction of migration and endocytosis. Recently, it has been reported that the CCR7-ligand chemokine-induced rapid uptake of Ag by mature DCs does not necessarily lead to efficient presentation of Ag on the cell surface (46). Consequently, it is presumed that the endocytosis of mature DCs plays different functional roles from immature DCs, such as rapid removal of the bacteria (46).

In circulating T cells, which require S1P3 for egress from lymph nodes, FTY720 and other S1P1 agonists cause S1P1 inactivation via receptor down-regulation and induce sequestration of circulating lymphocytes into secondary lymphoid tissues and the thymus. This demonstrates their immunosuppressive effects against several types of autoimmune disorders (18, 20, 39, 47). DCs migrate to lymph nodes through afferent lymphatic vessels, whereas T cells do so via high endothelial venules (1, 2). Both processes for entry are dependent on CCR7. Our preliminary results suggested that the process for entry did not depend on S1P1 because LPS-stimulated mature DCs prepared from S1P3-knockout mice injected into the mouse footpad can migrate to draining lymph nodes (Y. Maeda, K. Sugahara, and K. Chiba, unpublished observation).

In contrast to T cell migration, it has been widely believed that after DCs migrate to a lymph node they die there and do not leave through efferent lymphatic vessels (48, 49). This idea was based...
partly on the experimental difficulties in detecting the few DCs in the efferent lymph. Recently, Cavanagh et al. (50) reported that DCs are found not only in the blood but also in thoracic duct lymph in mice, suggesting that they can reenter the circulation from the periphery. Therefore, DCs released into the efferent lymph would reach the bloodstream and might have an effect on the induction of immune responses in distal organs. Indeed, injection of DCs into the skin can lead to priming of T cells in the spleen: suggesting that DCs can migrate into the bloodstream from the skin or skin-draining lymph nodes (51). Furthermore, Bonasio et al. (52) reported that circulating DCs can home to the thymus and induce clonal deletion of developing Ag-specific T cells in the thymus, suggesting that peripheral DCs may contribute to central tolerance. In conclusion, we provide evidence that S1P-induced migration of murine mature DCs and T cells is mediated by S1P3 and S1P1, respectively. Therefore, S1P1 may be also involved in the egress of DCs from lymph nodes, as well as S1P1, on T cells. To clarify the role of S1P1 on DC migration in vivo, we are currently analyzing turnover of DCs under steady-state or inflammatory conditions in S1P1−/− knockout mice.

Acknowledgments

We thank Drs. Masatoshi Kiuchi, Masao Chino, and Kunitomo Adachi for synthesizing (S)-FTY720-P and SEO2171 and Dr. Kazunori Iwata, Noriko Sato, and Sachiko Mochizuki for technical assistance in the experiments using S1P-knockout mice.

Disclosures

The authors have no financial conflict of interest.

References